Lv6
1740 积分 2022-01-27 加入
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor
2天前
已完结
Second-Line Treatment with Axitinib Plus Toripalimab in Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study
2天前
已完结
Efficacy of Second-Line ICIs Combined with TKIs among Patients with Metastatic Renal Cell Carcinoma: A Real-World Study
2天前
已完结
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
2天前
已完结
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
6天前
已完结
Global epidemiology of kidney cancer
7天前
已完结
Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions
17天前
已完结
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma
17天前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
17天前
已完结
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study
24天前
已完结
皖公网安备34019202002308
